Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
NCT ID: NCT00556530
Last Updated: 2025-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2016-07-31
2029-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study
NCT00105274
Genetics and Psychopathology in the 22q11 Deletion Syndrome
NCT00161109
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
NCT00758108
GROWing Up With Rare GENEtic Syndromes
NCT04463316
Molecular Variants Associated With Schizophrenia: Differential Analysis of Monozygotic Twins With Variable Phenotypic 22q11
NCT04141540
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
NOTE: Each clinical site is under the governance of its own Institutional Review Board and discretionary clinicaltrials.gov registration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Children's Hospital of Philadelphia
OTHER
University of Geneva, Switzerland
OTHER
University of Toronto, Centre for Addiction and Mental Health (CAMH)
UNKNOWN
Bambino Gesù Children's Hospital IRCCS
OTHER
University of California, Los Angeles
OTHER
Cardiff University
OTHER
Universidad del Desarrollo
OTHER
Tel Aviv University
OTHER
KU Leuven
OTHER
Maastricht University
OTHER
The Coriell Institute
UNKNOWN
National Institute on Aging (NIA)
NIH
Albert Einstein College of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bernice E. Morrow, PhD
Role: PRINCIPAL_INVESTIGATOR
Albert Einstein College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Albert Einstein College of Medicine
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.